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Margin reductionBackground and purpose: Intensity modulated radiotherapy requires all target areas to be treated by a sin-
gle radiotherapy plan. In anal cancer, the pelvic nodes, inguinal nodes and primary tumour represent
three different targets. We aim to calculate target-specific motion in anal cancer radiotherapy, when
delivered using a single pelvic online auto-match.
Materials and methods: Twenty consecutive patients treated using IMRT at a single institution were stud-
ied. CBCTs were retrospectively re-matched around the inguinal nodes and primary tumour. Match val-
ues were recorded relative to origin, defined as pelvic CBCT auto-match. Systematic and random errors
were quantified to determine target-specific motion and suggested margins calculated using van Herk
formulae.
Results: The suggested margins to cover the independent motion of the inguinal and anal targets for LR,
CC and AP set up around the inguinal nodes were 1.5 mm, 2.7 mm and 2.8 mm; and the primary tumour
were, 4.6 mm, 8.9 mm and 5.2 mm respectively.
Conclusions: Target-specific set up will likely result in reduced treatment volumes and as such reduced
toxicity. This is the first time a relationship has been described between pelvic bones, inguinal nodes
and primary tumour. The PLATO study will prospectively assess the toxicity and outcomes of this
target-specific margins strategy.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 121 (2016) 92–97
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Radical chemoradiotherapy (CRT) is the standard treatment for
squamous cell carcinoma of the anal canal, achieving local control
rates of 73% at 3 years [1,2]. Squamous cell carcinoma of the anus is
a loco-regional disease with spread into the regional pelvic and
inguinal nodes. Only <13% of patients present with distant disease
[3]. As such, during CRT, the primary tumour and involved nodes
receive a tumoricidal dose of radiation while the remaining
regional pelvic and inguinal lymph nodes receive an elective dose
with the aim of eliminating microscopic disease.
Intensity modulated radiotherapy (IMRT) is now used to
conform the radiotherapy plan around target volumes resulting
in reduced toxicity [4]. IMRT is delivered using a simultaneous
integrated boost (SIB) to cover the primary tumour, involved nodes
and the elective nodes within the same inverse planned IMRT
delivery. The elective nodes include the pelvic nodes, namely inter-
nal and external iliac, obturators, presacral and lower section of
mesorectal nodes, and the inguinal nodes.
In IMRT, the gross tumour volume (GTV), clinical target volume
(CTV), and planned target volume (PTV) are created in accordancewith ICRU 50, 62 and 83 [5–7]. The CTV to PTV margin is often
referred to as the ‘‘set up margin” and incorporates a number of
potential errors, the largest being internal target motion of the
CTV over the 5½ week of radiotherapy [8,9]. In anal cancer radio-
therapy, there are 3 geographically distinct targets: the pelvic
lymph nodes, inguinal lymph nodes and the primary anal tumour
or gross tumour volume (GTV_A). Due to the differing surrounding
muscle groups and organs, we hypothesise these three targets have
varying degrees of motion and as such require individualised CTV
to PTV margins. The defining of margins for different targets has
already been investigated in prostate, cervix and bladder cancer
where the primary tumour and elective nodal groups move
independently [10–13].
Chen et al. investigated margins in anal cancer. They used a
5 mm margin from CTV to PTV and a bony pelvis auto-match on
a Megavolt Cone Bean CT (MVCBCT) for verification. They analysed
whether further margins were required with and without the use
of daily online imaging, suggesting that with the use of daily imag-
ing a 5 mm margin was adequate [14]. As CBCT and kilo Voltage
(kV) imaging are comparable in calculating shifts based on pelvic
matches, this study would suggest that with 5 mm margin, the
elective pelvic nodal volume is adequately covered using daily
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the inguinal nodes or anus, while using a pelvic auto-match was
not assessed or incorporated, into the margin calculation.
The issue with a standard set up margin around all three anal
cancer targets is the potential for either geographical miss in areas
where there is increased motion; or increased toxicity where the
margin which covers the most mobile target being unnecessarily
large for the more static targets. Chen et al. confirmed that the
smaller margins reduced the doses to organs at risk [14]. Robinson
et al. also reported a similar finding with reduced bone marrow
toxicity using smaller margins [15]. Radiation to these different
targets results in different toxicities. Whole pelvis versus prostate
alone studies have demonstrated that irradiation of pelvic nodes
results in increased gastrointestinal toxicity [16,17]. Treatment of
inguinal nodes is associated with dermatitis, groin pain and lym-
phoedema of the legs [18]. In addition, when the set up margin
is added to create the PTV, the inguinal volumes increase the dose
to the genitalia causing toxicities such as vaginal stricturing, fistu-
las, dryness and dyspareunia [19]. Lastly the major toxicity of anal
irradiation is ulceration and faecal incontinence [20]. As such it is
important to use accurate, target-specific margins to minimise
each of these associated toxicities.
This study aims to quantify the target-specific CTV to PTV
growth to aid in the decision process in determining adequate
margins required in the elective inguinal nodes and primary anal
tumour when using an online CBCT image guided radiotherapy
(IGRT) protocol.Materials and methods
Patient selection
Twenty consecutive anal cancer patients, treated between 2013
and 2015, at Oxford University Trust; were evaluated within this
retrospective study. Patients had a diagnosis of squamous cell car-
cinoma; had completed full dose chemoradiotherapy to primary
tumour and all elective nodes according to United Kingdom (UK)
IMRT guidelines [21,22]; did not have a hip prostheses; and had
uninvolved inguinal nodes as determined radiographically by
FDG_PET and MRI imaging.Fig. 1. Planning CT scan demonstrating the VOI used for the primary tumour (VOI_Anal
used for pelvic auto-match (green contour) in (A) Sagittal, (B) Axial and (C) Coronal slicTreatment
Patients were immobilised supine with a comfortably full blad-
der, indexed knee support under the popliteal fossa and ankles
stocks. Treatment was delivered over 28 fractions. Volumes were
delineated as per UK guidance [21,22] by an experienced clinician
on a 2.5 mm contrast enhanced planning CT. In summary the pri-
mary gross anal tumour (GTV_Anal) was delineated and enlarged
by 25 mm to create PTV_Anal (15 mm CTV and 10 mm for PTV)
which received 50.4 or 53.2 Gy according to stage. The involved
pelvic nodes were delineated plus a margin of 20 mm to create
PTV_Nodes and treated to a dose of 50.4 Gy. Lastly the elective
node volume (CTV_Elective) was delineated and enlarged by
10 mm to create PTV_Elective which received 40 Gy. Both elective
nodal targets were delineated or edited to exclude local muscles
and bones. Treatments were inversely planned using 7–9 field
IMRT with a simultaneous integrated boost.
Chemotherapy was delivered with Mitomycin C 12 mg/m2 on
day 1 and Capecitabine 825 mg/m2 twice daily on all days of
radiotherapy.
Patients underwent daily imaging using a Varian Clinac IX with
OBI (CBCT) (Varian Medical Solutions, CA, USA). On fractions 1–5,
10, 15, 20, 25 a CBCT was performed with paired orthogonal kV
imaging all other fractions. Online pelvic auto-match was per-
formed daily. Initially an auto-match including pitch, yaw and roll
rotation was performed. If rotation was <3 mm a further pelvic
auto-match was performed without rotation, prior to shifts and
treatment. The patient was repositioned and re-imaged if rotation
was >3 degrees.Retrospective image matching
Twenty patients with 9 CBCTs each were analysed. The 180
CBCTs underwent 3 matches (pelvic, inguinal, and anal) summat-
ing 540 matches.
For matching purposes CTV_Elective was modified to create one
further volume of interest (VOI), the inguinal node volume
(VOI_Inguinal) encompassing the inguinal nodes alone. The
GTV_Anal was used as the anal VOI (VOI_Anal). The different vol-
umes of interest are illustrated in Fig. 1., red contour) and the inguinal nodes (VOI_Elective, light blue contour) and the ROI
es.
Table 1
Patient and tumour characteristics.
All patients (n = 20)
Age (y), median (range) 54 (39–73)
Gender
Male 5
Female 15
T stage
T1 5
T2 11
T3 3
T4 1
N stage
N0 15
N1 4
N2 0
N3 1
RT dose to primary tumour (Gy)
50.4 Gy 12
53.2 Gy 8
GTV_A Volume (cc’s), median (range) 33.6 (3–175)
94 Target-specific margins in anal cancerThree matches were performed to represent our departmental
standard range of corrections; lateral or left/right (LR), longitudinal
or cranial/caudal (CC) and vertical or anterior/posterior (AP) were
permitted. Rotations were not measured, nor corrected.
(1) A rigid, pelvic auto-match using a region of interest (ROI) to
encompass the bony pelvis. ROI borders were: the anterior
border of the symphysis pubis, anterior border the sacrum,
femoral heads laterally and the full extent of the CBCT image
(16 cm on a Varian Clinac IX). The values for the pelvic
match were recorded to act as a point of origin and reference
for further matches.
(2) A rigid, auto-match to VOI_Anal.
(3) A rigid, auto-match to VOI_Inguinal.
Matches were assessed visually by an experienced radiographer
to ensure clinical relevance and analysis pooled by combining the
measurements from all 9 CBCT images for each patient.
All matches used the registration module of Eclipse Treatment
Planning System Version 13 (Varian Medical Systems, CA, USA).Abbreviations: BMI = RT, radiotherapy; GTV, gross tumour volume.Systemic and random motion calculations
We are interested in the inter-fractional variation of the posi-
tion of the VOI under investigation with respect to the bony anat-
omy. The use of the word ‘‘motion” indicates this variation in the
remainder of the text.
To calculate motion for the inguinal nodes and primary tumour
relative to the pelvic bones; the shift from the pelvic auto-match to
the VOI_Inguinal and VOI_Anal respectively was calculated. The
systematic (R) and random motion (r) was calculated for both
areas for all 3 degrees of freedom as per Van Herk et al. publication,
and which is reflected in the IPEM guidance document [23,24].Target-specific margin calculations
Van Herk et al. equation (2.5R + 0.7r) was used to propose
target-specific motion for inguinal nodes and primary tumour
[24]. While this equation is routinely used to calculate set up mar-
gins, we have used it in this case to quantify the motion in order to
guide the determination of a PTV margin for each target.Fig. 2. Patient where the CBCT pelvic bony auto-match resulted in good alignment
of the inguinal target (green contour) but poor alignment of anal target (red
contour). (For interpretation of the references to colour in this figure legend, theReproducibility analysis
To ensure reproducibility and consistency of matches to VOI_In-
guinal and VOI_Anal, the auto-matches for day 2 CBCT, in all 20
patients were repeated a further 2 times, by the same observer,
summating 120 matches. The standard deviation (SD) of these 3
auto-matches was then calculated.
The data were then pooled by calculating a mean from each
match in each direction for both inguinal and primary tumour
targets.reader is referred to the web version of this article.)Results
Patient and tumour demographics are documented in Table 1.
387 of 540 (85.8%) of individual VOI_Inguinal matches were
equal or smaller than the comparably matched VOI_Anal match
relative to the pelvic auto-match. The range of individual inguinal
node matches (mm) were2.4 to 2.2,8.5 to 7.3,4.6 to 6.4 in the
LR, CC and AP directions respectively; and 9.8 to 4.2, 13.3 to
17.2, 6.9 to 12.7 respectively in the primary tumour matches.
Fig. 2 illustrates a patient were the pelvic match aligns well with
VOI_Inguinal but poorly with VOI_Anal.The pooled analysis for each patient demonstrated that inguinal
node matches conformed more closely to the pelvic auto-match
than the primary tumour in all directions (Fig. 3).
The differences between the shifts between the inguinal nodes
and the primary target demonstrate while there is more correla-
tion between the shifts in the lateral direction, the two targets
move independently in terms of both distance and direction to
each other (Fig. 4).
Fig. 3. VOI_Anal (grey area) and VOI_Inguinal (white area) auto-matches for each patient in 3 degrees of freedom. Red line indicates median; box represents the 25th and
75th centiles; whiskers the minimum and maximum measured values. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
Fig. 4. Difference in motion between the inguinal node and primary tumour targets in lateral, longitudinal and vertical directions.
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In all cases the systematic and random errors were larger for the
primary tumour than the inguinal nodes, they are documented in
Table 2.Target-specific set up calculations
The suggested margins, to incorporate the target-specific
motion for LR, CC and AP directions around the VOI_Inguinal were
2 mm, 3 mm and 3 mm respectively. Around VOI_Anal the margin
required to encompass the increased motion of this target were
5 mm, 9 mm and 5 mm respectively.Table 2
Patient and Tumor characteristics.
Lateral
(cm)
Longitudinal
(cm)
Vertical
(cm)
Rotational
(cm)
VOI_Anal
Mpopulation 0.2 0.7 0.3 0
Rpopulation 1.5 2.7 1.5 0
rpopulation 1.1 2.8 1.8 0
rpopulationRMS 1.2 3 2 0
VOI_Inguinal
Mpopulation 0 0.2 0.3 0
Rpopulation 0.4 0.7 0.9 0
rpopulation 0.6 1.2 0.8 0
rpopulationRMS 0.6 1.4 0.9 0
Abbreviations: Mpopulation = overall population mean set-up error;
Rpopulation = population systematic set-up error; rpopulation = random set-up error;
rpopulationRMS = population random error using root mean square.Reproducibility of matches
The mean (SD) of all the standard deviations for each match in
LR, CC and AP directions was 0.44 mm (0.31), 0.88 mm (0.95) and
0.75 mm (0.71) respectively in the inguinal node matching and
0.42 mm (0.28); 1.18 mm (0.87), 0.73 mm (0.61) respectively in
the primary tumour match. The majority of deviations is sub-
millimetre and confirms the auto-match process is reliable.
The standard deviation of the 3 repeated matches in each direc-
tion for the two targets is shown in Supplementary material Fig. 5.Discussion
To our knowledge the concept and quantification of target-
specific motion has not been described previously in anal cancer.
In this study we have quantified the motion around the inguinal
nodes and primary tumour, and offer appropriate margins to
ensure adequate coverage and reduce un-necessary toxicity; which
can be prospectively verified.
In the clinical application of these data, it must be acknowl-
edged that standard isotropic margins are often chosen for ease
of use. In addition, although the motion of the CTV over the treat-
ment course is the predominant factor in CTV to PTV margins,
there are other potential errors for example interclinician variation
in delineation, table sag, laser calibration, etc. Finally, the accuracy
of different linear accelerators must be considered; when consider-
ing margins <3 mm it must be acknowledged that some linear
accelerators do not have this degree of accuracy in delivery and
slice thickness of some scanners may exceed the set up. As such
we would suggest the use of 10 mm from CTV_Anal to PTV_Anal
96 Target-specific margins in anal canceras a pragmatic compromise. It must also be taken into account that
the GTV_Anal was used as the VOI_Anal, therefore an additional
margin from GTV_Anal to CTV_Anal must be used for microscopic
disease prior to adding the set up margin. Similarly the pragmatic
margin for CTV_Inguinal to PTV_Inguinal would be 5 mm.
Our study did not investigate rotational moves however the
three degrees of freedom investigated, represent the online correc-
tions performed on the majority of standard linear accelerators and
therefore our study is appropriate for the purposes of calculating
set up for routine clinical care.
It must be noted that the matches and as such the errors and
margins calculated are only relevant for similar verification tech-
niques, ROIs / VOI, threshold for shifts and matches. For centres
using different delineation techniques for their elective inguinal
nodes, or imaging/matching techniques or frequencies, or have a
minimum threshold for shifting; a centre specific margin should
be calculated. In addition, individual centres not involved in large
scale audits or trials should intermittently prospectively assess
these margins and outcomes to ensure they are unchanged by
slight changes in matches or delineation, by changes in staff or
equipment.
We selected patients without involved inguinal nodes. The
authors had concerns that the soft tissue auto-match may have
been improved by the incorporation in the VOI of a defined large
node. By selecting patients without involved nodes the calculation
of set up is performed without the benefit of defined lymph nodes
and as such would be appropriate for all anal cancer patients with
and without nodes as this margin is required around elective nodes
even in those patients that are node positive.
Further patient specific patient individualisation may be possi-
ble for outliers who require bigger margins. If these patients can be
identified prior to treatment, appropriate margins can be used
from outset. Factors that could affect the required margins include
patient sex, BMI, tumour size, location, bowel and bladder filling at
outset. Alternatively a number of adaptive planning techniques
have been suggested such as the use of a ‘‘multiple adaptive plan”
where multiple plans are created at outset and a plan of the day is
selected, the use of an adaptive morphing algorithm or daily plan
adjustment following online image assessment [25–27]. Anecdo-
tally the image quality, bowel gas and tumour shrinkage, were fac-
tors that affected the anal match.
Previously the UK IMRT guidance suggested 10 mm CTV to PTV
margin around the inguinal nodes which our study suggests could
be reduced to 5 mm. The Anal GTV to CTV and CTV to PTV margins
were previously combined in the UK IMRT guidance suggesting a
total margin of 25 mm. Data from skin squamous cell carcinoma
would suggest 11 mm in early disease and 14 mm in locally
advanced disease is an appropriate margin for microscopic disease
[28]. Therefore in early disease 20 mm GTV_Anal to PTV_Anal
(GTV_Anal to CTV_Anal = 10 mm + CTV_Anal to PTV_Anal =
10 mm) and in locally advanced disease suggested GTV_Anal to
PTV_Anal margin of 25 mm (GTV_Anal to CTV_Anal = 15 mm +
CTV_Anal to PTV_Anal = 10 mm).
In terms of margins used internationally; the RTOG 0529 proto-
col suggested a 1 cm CTV to PTV margin [29] while the TROG atlas
recognise the different verification protocols may allow different
margins, suggesting 5–7 mm with daily online imaging and
10 mm without [30]. The numerous series published used a wide
range of CTV to PTV margins ranging from 5 mm to 15 mm
[31–34] but none of the published literature suggests individu-
alised margins for different targets. This widespread variation
suggests there remains uncertainty regarding the correct margin
and the need for studies similar to our own.
While the quantification of margins is essential in anal radio-
therapy, other potential errors in the move to IMRT must be
addressed. Delineation and planning discrepancies are problematicin the move from conformal treatment to IMRT in anal cancer.
RTOG 0529 had a thorough quality assurance programme and
reported 33% had incorrectly delineated inguinal node compart-
ments. 81% had unacceptable plans initially, despite clear delin-
eation and planning instructions and an atlas; and 46% had
continued unacceptable plans following feedback. As such it is
important to audit and report outcomes of large series after imple-
mentation such as the national UK audit of IMRT in anal cancer
[35].
Chen et al. already reported reductions in standard margins
across different target areas reduced the dose to organs at risk
[14]. Although dosimetric modelling of consequences to organs
at risk using these target-specific margins could be performed,
the prospective assessment of toxicity and outcomes within a large
international trial is far superior method of assessment. The
upcoming PLATO study (ISRCTN88455282), investigating individu-
alised radiotherapy doses, plans to incorporate these margins and
has a built in safety and toxicity pilot which will assess these.Conflicts of interest statement
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